Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Bipolar 1 Disorder

In brief

Bipolar disorder (BPD) is a chronic debilitating illness characterized by drastic swings in mood, energy and functional ability that affects the adult population. Endoxifen is an active metabolite of the marketed drug Tamoxifen and the present study aims to evaluate the efficacy and safety of 8 mg endoxifen in the Bipolar I disorder patient population compared to a placebo arm. Endoxifen will be compared to a placebo to demonstrate that the test product is active and to establish that the study is sufficiently sensitive to detect differences between the investigational products. Thus, Endoxifen will be compared to placebo to demonstrate that the test product is safe and active.

Key facts

Study ID

NCT06608641

Run by

Jina Pharmaceuticals Inc.

People needed

490

Starts

2024-03-19

Expected to finish

2025-12-01

Last updated by the study team

2025-03-17

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male ≥18 to ≤65 years of age and postmenopausal female patients (12 months with no menses without an alternative medical cause) willing to give written informed consent along with at least one first degree relative (the legally acceptable representative [LAR]) to participate in the study before initiating any study related procedures.
• Six months of spontaneous amenorrhea with serum FSH levels \>40 mIU/mL; OR have had surgical bilateral oophorectomy (with or without hysterectomy) at least six months ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment if she is considered not of child-bearing potential.
• Patients must have a diagnosis of bipolar I disorder and currently display an acute manic episode with or without mixed features according to DSM-5 criteria as judged by the Investigator.
• Young Mania Rating Scale (YMRS) total score of \> 25 and ≥4 on two of four core items (irritability, speech, content, disruptive/aggressive behavior) at screening and at randomization (baseline). The optimal YMRS23 severity threshold of 25 was chosen as this corresponds to a Positive Predictive Value (PPV) of 83%, signifying that 83% of patients with a baseline score ≥ 25 are at least "Markedly ill".
• Score of \>4 in Severity of illness criteria of Clinical Global Impressions- bipolar disorder (CGI-BP) Scale for overall illness at screening and at randomization (baseline).
• Ready for voluntary hospitalization (along with the accompanying LAR if required and as advised by the Investigator) for the current manic episode for a minimum of 2 days prior to randomization through 21 days of in-patient treatment period.
• Last intake of the medication(s) for BPD should be 2-7 days prior to randomization depending upon the individual drug's plasma half-life.
• Patient and / or LAR understand and agree to comply with all the study requirements.
• Male patients of child begetting potential must be practicing adequate contraception, and any female partners must agree to the use of, highly effective contraception. Documentation should be provided for surgical sterilization for male patients not of child begetting potential.
• Patient has not taken and agrees not to take any medication or therapy prohibited by the protocol (refer to listing in Section 14.7) for the entire study period.
• Patients not having any significant diseases or clinically significant abnormal findings except BPD during screening-including medical history, physical examination, laboratory evaluations, 12-lead ECG and X-ray chest (postero- anterior view) recording, etc. which is likely to adversely affect patient\'s safety and may impact the clinical outcome of the study by participating in the study or study objectives in Investigator\'s opinion.
• Subjects judged clinically not to be at serious suicide risk, (all responses to the Baseline C-SSRS as "No"), or homicidal risk per clinical questioning.

You may not qualify if…

• Newly diagnosed patients not having any suitable treatment exposure in the past for their bipolar mood disorder.
• ≥ 20% improvement in YMRS total scores between screening and randomization visits.
• Patients who meet DSM-5criteria for any psychiatric disorder other than Bipolar I Disorder with Acute manic episodes with or without mixed features
• Patients with seizure disorder
• Obsessive compulsive disorder or any other co-morbid Axis I anxiety disorder
• Patients with borderline or anti-social personality disorder of sufficient current severity to interfere with conduct of the study
• Patients with classical premenopausal symptoms were found at risk of developing intolerable hot flushes, irregular vaginal bleeding.
• Use of the following medications:
• Antihypertensive agents if stable dose has not been administered for at least 1 month before randomization
• Antidepressants in the week (or a period of 5 half-lives of the drug) prior to randomization
• Continuous daily or standing orders use of benzodiazepines during the month preceding screening (approximately 5 weeks prior to screening)
• Potent cytochrome P450 (CYP) inducers and CYP2D6/CYP3A4 inhibitors 14 days prior to randomization
• Depot antipsychotic medications within 1 dosing interval prior to randomization
• Use of systemic estrogens 6 weeks prior to randomization
• Patients currently on carbapenem agents
• Any of the following laboratory abnormalities
• Serum bilirubin ≥ 1.5 times ULN
• Serum AST/ALT ≥ 2.5 times ULN
• Serum TSH \>10% above the ULN, regardless of treatment for hypothyroidism or hyperthyroidism
• Serum triglyceride level \> 2.5 times ULN
• Patients with the following cardiac conditions are excluded:
• Recent myocardial infarction (\<12 months)
• QTc prolongation (screening electrocardiogram with QTc \> 450 msec for men, QTc \> 470 msec for women)
• History of QTc prolongation or using concomitant medications (as judged by the Investigator) which prolong QTc interval
• Sustained cardiac arrhythmia or history of sustained cardiac arrhythmia

Where it is running

• Synexus — Cerritos, California, United States
• NRC Research Institute — Los Angeles, California, United States
• NRC Research Institute — Orange, California, United States
• Medical Research of Westchester, Inc. — Miami, Florida, United States
• Sunshine Medical Research Studies Inc. — Miami, Florida, United States
• Innovative Clinical Research, Inc. — Miami Lakes, Florida, United States
• South Florida Research Phase I-IV, Inc. — Miami Springs, Florida, United States
• Santos Research Center, CORP — Tampa, Florida, United States
• Accelerated Clinical Trials, LLC — East Point, Georgia, United States
• Accelerated Clinical Trials, LLC — Norcross, Georgia, United States
• Accelerated Clinical Trials, LLC — Peachtree Corners, Georgia, United States
• Precise Research Centers — Flowood, Mississippi, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.